Tazemetostat

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 283 publications

Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities.

Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities.

Journal: Current opinion in oncology

Published: March 24, 2026

Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives.

Pyridone-based EZH2 inhibitor anticancer candidates: synthetic approaches, comparative analysis, and future perspectives.

Journal: Future medicinal chemistry

Published: February 24, 2026

Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation.

Crotonate suppresses breast cancer metastasis and promotes immunotherapy response by inducing ACSS2-mediated EZH2-K348 crotonylation.

Journal: Science advances

Published: January 16, 2026

Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells.

Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells.

Journal: International journal of molecular sciences

Published: January 05, 2026

EZH2 Inhibition Restores Tumor Suppressor SFRP1 Activity by Reprogramming Extrachromosomal Circular DNA Dynamics in Ovarian Cancer.

EZH2 Inhibition Restores Tumor Suppressor SFRP1 Activity by Reprogramming Extrachromosomal Circular DNA Dynamics in Ovarian Cancer.

Journal: Biology

Published: December 26, 2025

Update on pediatric soft tissue sarcomas.

Update on pediatric soft tissue sarcomas.

Journal: Current opinion in pediatrics

Published: December 26, 2025

Post-Marketing Safety of Tazemetostat in Antitumor Therapy: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

Post-Marketing Safety of Tazemetostat in Antitumor Therapy: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

Journal: Cancer investigation

Published: December 19, 2025

Enhancing Triple-Negative Breast Cancer Radiotherapy via EZH2-Targeted Nanoplatform and Radionuclide Therapy.

Enhancing Triple-Negative Breast Cancer Radiotherapy via EZH2-Targeted Nanoplatform and Radionuclide Therapy.

Journal: Molecular pharmaceutics

Published: November 22, 2025

Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives.

Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives.

Journal: RSC advances

Published: November 12, 2025

Therapeutic Horizons in Targeting EZH2 With Dual and Non-PROTAC Inhibitor Molecules: Recent Achievements, Comparative Analysis, and Future Perspectives.

Therapeutic Horizons in Targeting EZH2 With Dual and Non-PROTAC Inhibitor Molecules: Recent Achievements, Comparative Analysis, and Future Perspectives.

Journal: Archiv der Pharmazie

Published: November 10, 2025

High-Grade Angiosarcoma Transformation in Schwannoma and SMARCB1 Mutation: A Case Report.

High-Grade Angiosarcoma Transformation in Schwannoma and SMARCB1 Mutation: A Case Report.

Journal: The American journal of case reports

Published: October 21, 2025

Integrative bulk and single-cell transcriptomics link EZH2 to immunosuppressive programs and tumor-Treg crosstalk in castration-resistant prostate cancer.

Integrative bulk and single-cell transcriptomics link EZH2 to immunosuppressive programs and tumor-Treg crosstalk in castration-resistant prostate cancer.

Journal: Frontiers in immunology

Published: October 14, 2025

Showing 1-12 of 283

Last Updated: 04/28/2026